$ADMA Legal News: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action – Investors Notified to Contact BFA Law
Bleichmar Fonti & Auld LLP announced a class action lawsuit against ADMA Biologics regarding alleged securities fraud tied to channel stuffing claims. The lawsuit follows a March 24, 2026 report by Culper Research and subsequent stock declines, alleging ADMA misrepresented 2025 growth figures. Investors have until August 10, 2026, to seek lead plaintiff status in the U.S.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.